CN102319271A - 一种褥疮护理粉 - Google Patents
一种褥疮护理粉 Download PDFInfo
- Publication number
- CN102319271A CN102319271A CN201110284338A CN201110284338A CN102319271A CN 102319271 A CN102319271 A CN 102319271A CN 201110284338 A CN201110284338 A CN 201110284338A CN 201110284338 A CN201110284338 A CN 201110284338A CN 102319271 A CN102319271 A CN 102319271A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- seu calvatia
- lasiosphaera seu
- powder
- nursing care
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000474 nursing effect Effects 0.000 title claims abstract description 20
- 239000000843 powder Substances 0.000 title claims abstract description 16
- 208000004210 Pressure Ulcer Diseases 0.000 title claims abstract description 13
- 206010011985 Decubitus ulcer Diseases 0.000 title claims abstract description 12
- 241000959626 Calvatia Species 0.000 claims abstract description 29
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 22
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims abstract description 11
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 11
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims abstract description 11
- 229930003471 Vitamin B2 Natural products 0.000 claims abstract description 11
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 11
- 229960002477 riboflavin Drugs 0.000 claims abstract description 11
- 235000019164 vitamin B2 Nutrition 0.000 claims abstract description 11
- 239000011716 vitamin B2 Substances 0.000 claims abstract description 11
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 11
- 239000011718 vitamin C Substances 0.000 claims abstract description 11
- 239000002994 raw material Substances 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 abstract description 18
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 3
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 208000025865 Ulcer Diseases 0.000 description 16
- 231100000397 ulcer Toxicity 0.000 description 16
- 229940079593 drug Drugs 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 3
- 208000010445 Chilblains Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 230000002439 hemostatic effect Effects 0.000 description 2
- 230000008676 import Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 206010024604 Lipoatrophy Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 240000008866 Ziziphus nummularia Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 239000010231 banlangen Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229940046011 buccal tablet Drugs 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 229960003150 bupivacaine Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 201000010251 cutis laxa Diseases 0.000 description 1
- 238000001804 debridement Methods 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000002682 general surgery Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003692 ilium Anatomy 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229960003502 oxybuprocaine Drugs 0.000 description 1
- CMHHMUWAYWTMGS-UHFFFAOYSA-N oxybuprocaine Chemical compound CCCCOC1=CC(C(=O)OCCN(CC)CC)=CC=C1N CMHHMUWAYWTMGS-UHFFFAOYSA-N 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 210000000954 sacrococcygeal region Anatomy 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- -1 sublimed preparation Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960002372 tetracaine Drugs 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明公开了一种褥疮护理粉，它是由下述重量配比的原料药制成的粉剂：马勃6～10份，维生素C 0.3～0.6份，维生素B20.01～0.05份。该药剂以马勃为主要原料，并将马勃与其他消炎修复组分有机结合，使之协调作用进行褥疮护理，治疗效果突出，成本低廉。
Description
技术领域
本发明涉及一种创伤面护理用的药物，尤其涉及一种临床护理创面修复粉剂。
背景技术
褥疮，是长期卧床不起的患者由于躯体的重压和摩擦而引起的一种以局限性浅表皮肤破损、疮口经久不愈为主要表现的慢性疮疡类疾病。卧床者由于局部组织长期受压，发生持续缺血、缺氧、营养不良而致组织溃烂坏死。皮肤褥疮在康复治疗、护理中是一个普遍性的问题。据有关文献报道每年约有6万人死于褥疮合并症。褥疮的发生率已经成为医院护理质量优劣的标志，国外因发生褥疮提起诉讼并要求赔偿的案例逐年增加。老年人皮肤松弛干燥，缺乏弹性，皮下脂肪萎缩、变薄，成为褥疮的已发生人群。我国人口进入老龄化阶段，心脑血管老年病人不断增加，由于长时间卧床褥疮出现，加重了病情，延长了康复时间，增加了医疗费用，严重者感染引起败血症危及生命，使患者及家人身心痛苦。
治疗褥疮的药物较多，疗效也较显著；但是作为非处方的护理药物比较少见。现在临床上普通外科换药，用无菌纱布包扎，或者用一些进口的材料，费用极高，普通百姓难以承受；而且创面愈合效果不佳，愈合时间长，增加患者的身心痛苦和经济负担。
马勃是一种常用于止血的中药，发明专利申请02104346.9公开了一种马勃止血敷料及制备方法，该敷料是一种以马勃为主要成分并辅以其他组分的用于止血的药料；发明专利申请200910180215.5公开了一种马勃组合物及其应用，该组合药物以马勃或其提取物为主要活性成分，加入相辅的中药如甘草、连翘、板蓝根、薄荷的提取物，外敷制剂加入表皮麻醉剂利多卡因、丁卡因、布比卡因、奥布卡因、普鲁卡因等起到镇痛作用。该发明马勃组合药物的剂型包括片剂、含片、胶囊及软胶囊剂、颗粒剂、糖浆剂、微丸剂、微球剂、丹剂、水剂和外用膏剂、乳剂、贴剂、绷带或纱布浸液制成的马勃粉撒布、马勃絮垫、马勃绷带、马勃纱布。该组合物用于清肺利咽，消炎止血。也有将马勃用于治疗冻疮，用蜂蜜调和涂敷患处。但是，在医学上，外伤伤口出血与褥疮的形成有着不同的机制和护理方法，冻疮与褥疮也有不同的护理方法和治疗机制，马勃在护理褥疮领域，尤其是和一些具有消炎、修复功能的组分相结合进行褥疮护理，并未被人们所研究应用；临床上也未见将止血用的马勃药物或者其他含有马勃的药物用于褥疮护理。
发明内容
本发明所要解决的技术问题是提供一种褥疮护理粉，该粉剂以马勃为主要原料，并将马勃与其他消炎修复组分有机结合，使之协调作用进行褥疮护理，治疗效果突出，成本低廉。
为了解决上述技术问题，本发明采取以下技术方案：
一种褥疮护理粉，其特征在于它是由下述重量配比的原料药制成的粉剂：马勃6～10份，维生素C 0.3～0.6份，维生素B20.01～0.05份。
所述原料药重量配比优选：马勃8份，维生素C 0.5份，维生素B20.03份。
本药剂中，马勃有止血消炎，吸附体液的作用，维生素C能促进骨胶原的生物合成，利于组织创伤口的更快愈合，增强肌体对外界环境的抗应激能力和免疫力，促进胶原蛋白的合成；维生素B2能参与细胞的生长代谢，提供肌体组织代谢和修复的必需营养，保护皮肤毛囊粘膜及皮脂腺的功能。
更为关键的，马勃、维生素C和维生素B2合用，体现出了一种单个组分所远远不能发挥的协同作用，虽然产生这种协调作用的机理尚不清楚，但是在临床上，通过使用各组分特定配比的粉剂，已经取得了现有药物无法达到的护理和治疗效果。本药剂组分简单，成本是否低廉，是一种可以大规模推广使用的褥疮良好护理药物。
具体实施方式
下述实施例中，每份为1克。
实施例一：
原料药重量配比为马勃6份，维生素C 0.3份，维生素B20.01份。
实施例二：
原料药重量配比为马勃10份，维生素C 0.6份，维生素B20.05份。
实施例三：
原料药重量配比为马勃8份，维生素C 0.5份，维生素B20.03份。
实施例四：本发明应用效果
2010年3月到2011年8月护理褥疮患者43例，男30例，女13例，年龄58-86岁，31例骶尾部II度褥疮，13例髂棘骨突出II度褥疮；均采用三种方法同体对照。A、用0.9％无菌生理盐水清创，待干后均匀涂上本品褥疮护理粉暴露护理法；B、采用进口减压贴(康乐宝公司)；C、常规外科换药包扎。结果如表一所示：
另外，对30例患褥疮的志愿者分别用马勃、维生素C、维生素B2单组份护理治疗，均无明显效果，不能用于临床护理。
表一：三种护理褥疮效果对比
Claims (2)
1.一种褥疮护理粉，其特征在于它是由下述重量配比的原料药制成的粉剂：马勃6～10份，维生素C 0.3～0.6份，维生素B20.01～0.05份。
2.如权利要求1所述的褥疮护理粉，其特征在于它是由下述重量配比的原料药制成的粉剂：马勃8份，维生素C 0.5份，维生素B20.03份。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110284338 CN102319271B (zh) | 2011-09-22 | 2011-09-22 | 一种褥疮护理粉 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110284338 CN102319271B (zh) | 2011-09-22 | 2011-09-22 | 一种褥疮护理粉 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102319271A true CN102319271A (zh) | 2012-01-18 |
| CN102319271B CN102319271B (zh) | 2013-05-08 |
Family
ID=45447197
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201110284338 Expired - Fee Related CN102319271B (zh) | 2011-09-22 | 2011-09-22 | 一种褥疮护理粉 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102319271B (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103083420A (zh) * | 2013-01-21 | 2013-05-08 | 长春中医药大学 | 一种治疗褥疮的中药组合物及其制备方法 |
| CN113730447A (zh) * | 2021-05-17 | 2021-12-03 | 南京中医药大学 | 一种促进创面愈合的中药和提取物及应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1442198A (zh) * | 2002-03-01 | 2003-09-17 | 崔建伟 | 一种马勃止血敷料及制备方法 |
| CN101027074A (zh) * | 2004-09-22 | 2007-08-29 | 味之素株式会社 | 复合肠内营养组合物 |
-
2011
- 2011-09-22 CN CN 201110284338 patent/CN102319271B/zh not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1442198A (zh) * | 2002-03-01 | 2003-09-17 | 崔建伟 | 一种马勃止血敷料及制备方法 |
| CN101027074A (zh) * | 2004-09-22 | 2007-08-29 | 味之素株式会社 | 复合肠内营养组合物 |
| CN101027074B (zh) * | 2004-09-22 | 2010-06-16 | 味之素株式会社 | 复合肠内营养组合物 |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103083420A (zh) * | 2013-01-21 | 2013-05-08 | 长春中医药大学 | 一种治疗褥疮的中药组合物及其制备方法 |
| CN113730447A (zh) * | 2021-05-17 | 2021-12-03 | 南京中医药大学 | 一种促进创面愈合的中药和提取物及应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102319271B (zh) | 2013-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11571452B2 (en) | Method of treating a skin wound with a liquid-state topical pharmaceutical composition | |
| Merz et al. | Fungating wounds–multidimensional challenge in palliative care | |
| CN102125634A (zh) | 一种治疗褥疮的中药组合物 | |
| WO2018137319A1 (zh) | 大叶清香桂的应用，治疗皮肤病的中药膏剂、制备方法及其应用 | |
| CN100420460C (zh) | 治疗烧烫伤的中药组合物及其制备方法和应用 | |
| EP3369428B1 (en) | External traditional chinese medicine preparation for diminishing inflammation, relieving pain and promoting fast healing, and preparation method therefor | |
| CN103330774A (zh) | 痔瘘坐浴液及其制备方法 | |
| CN103566071B (zh) | 一种治疗溃疡的外用中药组合物及其散剂的制备方法 | |
| CN102579655A (zh) | 治疗口腔溃疡的中药外敷制剂 | |
| CN102319271B (zh) | 一种褥疮护理粉 | |
| CN103977194A (zh) | 能有效治疗创面感染的外用药在制备治疗糖尿病足药物中的应用 | |
| CN101757347B (zh) | 断血创可贴及其制备方法 | |
| CN105560620A (zh) | 一种用于外伤处理的中药制剂 | |
| CN102872187B (zh) | 一种外用毒疮膏及其制备方法 | |
| CN102028875B (zh) | 一种治疗开放性外伤的药物及其制备方法 | |
| CN102727698B (zh) | 一种治疗褥疮的创面护理粉 | |
| CN101028365B (zh) | 一种治疗烧、烫伤的药物及其制备方法 | |
| CN101229193A (zh) | 一种治疗皮肤溃烂及肌体坏疽的外用中成药 | |
| CN101904998A (zh) | 一种治疗脚气的特效药物及其制备方法 | |
| CN104983936A (zh) | 一种临床护理上用于治疗三期褥疮的中药膏剂 | |
| CN101716191A (zh) | 一种治疗褥疮的外敷中药组合物 | |
| CN101757223B (zh) | 一种治疗牛皮癣的外用中药 | |
| CN100356965C (zh) | 纯天然烧烫药 | |
| CN1279947C (zh) | 治疗跌打损伤的药物 | |
| CN102920776A (zh) | 治疗伤口感染的药物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20170801 Address after: 071000 Yuhua East Road, Hebei, China, No. 212, No. Patentee after: Affiliated Hospital of Hebei University Address before: 071000 Department of cerebral surgery, Affiliated Hospital of Hebei University, Hebei, Baoding Patentee before: Li Yuanli |
|
| TR01 | Transfer of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130508 Termination date: 20180922 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |